FDA grants orphan drug designation to serplulimab for small cell lung cancer

The FDA granted orphan drug designation to serplulimab for treatment of small cell lung cancer.
Serplulimab (Hansizhuang, Shanghai Henlius Biotech) is a PD-1 inhibitor in development for first-line treatment of small cell lung cancer.
Small cell lung cancer — the most aggressive lung cancer subtype — accounts for an estimated 15% to 20% of lung cancer cases worldwide. It typically is associated with rapid disease progression, early metastasis and poor prognosis.
Standard treatment for limited-stage small cell lung cancer consists of surgery, chemotherapy and concurrent radiotherapy.

The FDA granted orphan drug designation to serplulimab for treatment of small cell lung cancer.
Serplulimab (Hansizhuang, Shanghai Henlius Biotech) is a PD-1 inhibitor in development for first-line treatment of small cell lung cancer.
Small cell lung cancer — the most aggressive lung cancer subtype — accounts for an estimated 15% to 20% of lung cancer cases worldwide. It typically is associated with rapid disease progression, early metastasis and poor prognosis.
Standard treatment for limited-stage small cell lung cancer consists of surgery, chemotherapy and concurrent radiotherapy.